Scalper1 News
JPMorgan raised its price target on Nevro (NVRO) to 42 from 34 and the stock rose 13% Monday, closing at an all-time high of 39.37. Nevro develops and markets an implantable spinal cord stimulation system called Senza, designed to treat chronic pain in the back and legs. The company raised $126 million on its Nov. 6 IPO, which priced at 18, above the estimated range of 15 to 17. In June, Nevro submitted its premarket approval application to the Scalper1 News
Scalper1 News